Table 1. Baseline patient characteristics and their association with TTR and OS in univariate analysis.
| TTR | OS | |||||
|---|---|---|---|---|---|---|
|
Parameter |
n |
% |
HR (95% CI) |
P-value |
HR (95% CI) |
P-value |
|
Gender | ||||||
| Male | 217 | 58.3 | 1 (reference) | 0.417 | 1 (reference) | 0.801 |
| Female |
155 |
41.7 |
1.19 (0.80–1.79) |
|
1.06 (0.66–1.70) |
|
|
Tumour location | ||||||
| Left | 130 | 34.9 | 1 (reference) | 0.781 | 1 (reference) | 0.273 |
| Right |
242 |
65.1 |
1.06 (0.69–1.63) |
|
0.77 (0.48–1.23) |
|
|
Tumour-invasion depth | ||||||
| T1 | 7 | 1.9 | 1 (reference) | 0.010 | na, because of the low number of events for T1 and T2 (T1–3 vs T4: 2.487 (1.53–4.04)) | <0.001 |
| T2 | 18 | 4.8 | 0.65 (0.06–7.17) | |||
| T3 | 260 | 69.9 | 1.43 (0.20–10.34) | |||
| T4 |
87 |
23.4 |
2.78 (0.38–20.36) |
|
|
|
|
Lymph node involvement | ||||||
| N0 | 156 | 41.9 | 1 (reference) | <0.001 | 1 (reference) | <0.001 |
| N1 | 142 | 38.2 | 1.47 (0.87–2.48) | 1.25 (0.69–2.26) | ||
| N2 | 73 | 19.6 | 4.02 (2.42–6.69) | 3.28 (1.85–5.83) | ||
| Unknown |
1 |
0.3 |
|
|
|
|
|
Tumour grade | ||||||
| G1 | 23 | 6.2 | 1 (reference) | 0.776 | 1 (reference) | 0.092 |
| G2 | 240 | 64.5 | 1.39 (0.51–3.83) | 0.78 (0.28–2.20) | ||
| G3 | 107 | 28.8 | 1.46 (0.51–4.16) | 1.34 (0.47–3.83) | ||
| Unknown |
2 |
0.5 |
|
|
|
|
|
Tumour stage | ||||||
| II | 154 | 41.4 | 1 (reference) | <0.001 | 1 (reference) | 0.017 |
| III | 217 | 58.3 | 2.36 (1.48–3.75) | 1.86 (1.12–3.11) | ||
| Unknown |
1 |
0.3 |
|
|
|
|
|
Adjuvant chemotherapy | ||||||
| No | 141 | 37.9 | 1 (reference) | 0.605 | 1 (reference) | 0.181 |
| Yes | 230 | 61.8 | 1.12 (0.73–1.72) | 0.73 (0.73–1.72) | ||
| Unknown | 1 | 0.3 | ||||
Abbreviations: CI=confidence interval; HR=hazard ratio; na=not applicable; OS=overall survival; TTR=time to recurrence.